If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

Share Price is delayed by 15 minutes
Get Live Data
6.75    0.25 (3.85%)
Bid:
6.70
Ask:
6.80
Spread: 0.10 (1.493%)
Market Cap: £2.96m
FDBK Live PriceLast checked at - London Stock Exchange

Intraday Feedback Share Chart

New Company Structure and Directorate Change

16 Apr 2018 07:30

RNS Number : 9478K
Feedback PLC
16 April 2018
 

This announcement contains inside information as stipulated under the Market Abuse Regulation (EU) No 596/2014 (MAR).

16 April 2018

Feedback plc

(the "Company" or "Feedback")

 

New company structure and changes to the Board of Directors

 

Cambridge, UK - 16 April 2018: Feedback plc ("Feedback" or the "Company") (AIM: FDBK), the specialist medical imaging technology company, announces a new company structure and changes to the Board of Directors to optimise Feedback's operations and continue to build the Company's presence in the field of medical imaging.

 

New company structure

Feedback acquired Cambridge Computed Imaging Ltd ("CCI") and TexRAD Limited in 2014, and both companies have been operating as wholly-owned subsidiaries since. As part of a strategic review to streamline operations and act as a fully-integrated organisation, CCI has been renamed to Feedback Medical Limited and TexRAD Limited will become dormant. All employees will be working for Feedback Medical Limited as a wholly-owned subsidiary of Feedback. These organisational changes are aligned to the Company's mission to create evidence-based imaging software, arming clinicians with innovative tools to improve patient outcomes.

 

Changes to the Board of Directors

As part of the organisational changes, Mike Hayball and Dr Balaji Ganeshan have resigned as Executive Directors of Feedback plc with immediate effect. Mike Hayball will continue as Director of Feedback Medical Limited and Dr Balaji Ganeshan has been appointed as a Director of Feedback Medical Limited. In addition, Dr Alex Menys has stepped down as Non-Executive Director with immediate effect having served on the Board since November 2015. Simon Sturge has been appointed as Non-Executive Director with immediate effect (see separate announcement). Furthermore, Dr Alastair Riddell and Simon Sturge will receive share options in lieu of fees to reduce board cash costs and a further announcement will be made when such options are granted.

 

Dr Alastair Riddell, Chairman of Feedback, said: "These changes represent an important step for Feedback to simplify its organisation and continue to leverage its global brand in the field of medical imaging. On behalf of the Board I would like to thank Dr Alex Menys for his support since 2015 as Feedback's progress has evolved. In streamlining the Board, we now have complementary expertise across the Non-Executive and Executive Directors and are well-positioned to support the Company's growth strategy."

 

David Crabb, Chief Executive Officer of Feedback, said: "Over the past two months I have been focused on unlocking the significant potential in optimising and expanding Feedback's operations. I believe that these organisational changes will unify the team, improve business performance and raise awareness of the Company globally. With two, well-established platform technologies and deep domain expertise, I look forward to delivering continued progress towards our long-term vision to lead global innovation in quantitative medical imaging analysis."

 

-- Ends --

 

Notes to editors

 

About Feedback plc

Feedback plc is a specialist medical imaging technology company. It develops software and systems that provide innovative techniques and improved workflows for practitioners involved in medical research and treating patients. TexRAD®, the Company's patented quantitative image texture analysis technology, has the potential to assist clinicians in diagnosis, prognosis and treatment of patients with cancer and is currently installed in over 40 of the world's leading research institutions across Europe, North America, Asia and Australasia. The Cadran platform provides a suite of medical imaging tools for decision support. The Cadran range includes the picture archiving communication system (PACS) to provide decision support for scan analysis, diagnostic workstations which provide secure remote access to view scans on demand, and products to securely share and transport patient data. Visit www.fbk.com.

 

For further information, please contact:

 

Feedback plc

David Crabb, Chief Executive Officer

Lara Mott, Investor Relations

 

Tel: 01954 718072

IR@fbk.com

Allenby Capital Limited (Nominated Adviser and Joint Broker)

David Worlidge / Asha Chotai

 

Tel: 020 3328 5656

Northland Capital Partners Ltd (Joint Broker)

David Hignell / John Howes

 

Tel: 020 3861 6625

Peterhouse Corporate Finance Ltd (Joint Broker)

Lucy Williams / Duncan Vasey

 

Tel: 020 7469 093

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBCGDSLSBBGIU
Date   Source Headline
22nd Apr 20262:10 pmRNSGrant of Options and PDMR dealing
20th Apr 20267:00 amRNSNHS Progress and Business Update
17th Feb 202610:43 amRNSCorrection: Half-year Report
17th Feb 20267:00 amRNSHalf-year Report
2nd Feb 20267:00 amRNSNotice of Results & Retail Investor Presentation
5th Jan 20264:13 pmRNSHolding(s) in Company
23rd Dec 20253:44 pmRNSHolding(s) in Company
23rd Dec 20253:44 pmRNSHolding(s) in Company
23rd Dec 20253:33 pmRNSDirector/PDMR Shareholding
23rd Dec 20253:33 pmRNSDirector/PDMR Shareholding
18th Dec 20257:00 amRNSTrading Update
20th Oct 20257:00 amRNSDirectorate Change
13th Oct 20254:04 pmRNSResult of AGM
18th Sep 20251:07 pmRNSNotice of AGM
17th Sep 20257:00 amRNSFinal Results
8th Sep 20257:00 amRNSNotice of Results & Retail Investor Presentation
10th Jul 20257:00 amRNSGrant of Options and PDMR dealing
12th Jun 20257:00 amRNS-RNeighbourhood Health Service Simulation
7th May 202510:44 amRNSHolding(s) in Company
6th May 20251:01 pmRNSHolding(s) in Company
28th Apr 20257:00 amRNSTrading Update
25th Feb 20257:00 amRNSHalf-year Report
11th Feb 20257:00 amRNSNotice of Results & Investor Presentation
14th Jan 20257:00 amRNSSurrender and grant of options and PDMR dealings
18th Dec 20243:07 pmRNSHolding(s) in Company
18th Dec 20247:00 amRNSHalf Year Trading Update
9th Dec 202410:56 amRNSHolding(s) in Company
9th Dec 202410:48 amRNSHolding(s) in Company
4th Dec 20247:00 amRNSHolding(s) in Company
3rd Dec 202412:33 pmRNSHolding(s) in Company
3rd Dec 202412:18 pmRNSHolding(s) in Company
2nd Dec 202411:53 amRNSHolding(s) in Company
2nd Dec 202411:46 amRNSHolding(s) in Company
2nd Dec 20247:00 amRNSDirector/PDMR Shareholding
29th Nov 20243:36 pmRNSHolding(s) in Company
29th Nov 20243:33 pmRNSHolding(s) in Company
28th Nov 20242:35 pmRNSResult of AGM & Commercial Update
6th Nov 20247:00 amRNSResult of WRAP Retail Offer
4th Nov 20243:46 pmRNSSuccessful Fundraising upscaled to c. £5.57m
4th Nov 20247:02 amRNSWRAP Retail Offer for up to £1 million
4th Nov 20247:01 amRNSProposed Fundraise & Share Capital Reorganisation
4th Nov 20247:00 amRNSFinal Results
16th Oct 20247:00 amRNSElective Recovery Fund funding mechanism
19th Sep 20247:00 amRNSCollaboration Agreement
2nd Sep 20247:00 amRNSFurther funding to extend NHS Trust pathways
10th Jul 20247:00 amRNSVertex In Healthcare Collaboration
1st Jul 20247:00 amRNSCDC Contract Awarded by Queen Victoria Hospital
28th Jun 20247:00 amRNSChange of Name of Nominated Adviser and Broker
22nd May 20247:00 amRNSTrading Update
25th Mar 20247:00 amRNSNew tuberculosis partnership in India

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.